Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: A FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Oberic, Lucie ^a   Viret, Frédéric ^b   Baey, Charlotte ^a   Ychou, Marc ^c   Bennouna, Jaafar ^d   Adenis, Antoine ^e   Peiffert, Didier ^f   Mornex, Françoise ^g   Pignon, Jean Pierre ^a   Celier, Patrice ^h   Berille, Jocelyne ⁱ   Ducreux, Michel ^a,j  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c CENTRE VAL D AURELLE   (France)

^d CENTRE RENÉ GAUDUCHEAU   (France)

^e CENTRE OSCAR LAMBRET   (France)

^f CENTRE ALEXIS VAUTRIN   (France)

^g CENTRE HOSPITALIER LYON SUD   (France)

^h CENTRE PAUL PAPIN   (France)

ⁱ FNCLCC   (France)

^j UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; ANTINEOPLASTIC AGENT; TAXOID;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DYSPEPSIA; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENERAL CONDITION DETERIORATION; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOTENSION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; VOMITING; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PANCREAS TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 80053379301     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-124     Document Type: Article

References (31)

1. Berrino F, Verdecchia A, Lutz JM, Lombardo C, Micheli A, Capocaccia R. Comparative cancer survival information in Europe, EUROCARE Working Group. Eur J Cancer 2009, 45:901-8. 10.1016/j.ejca.2009.01.018, 19217771.
2. Garcea G. Survival Following Curative Resection for Pancreatic Ductal Adenocarcinoma. A Systematic Review of the Literature. JOP J Pancreas (Online) 2008, 9:99-132.
3. Keleg S, Büchler P, Ludwig R, Büchler MW, Friess H. Invasion and metastasis in pancreatic cancer. Molecular Cancer 2003, 2:14. 10.1186/1476-4598-2-14, 149416, 12605717.
4. Jacobs NL, Que FG, Miller RC, Vege SS, Farnell MB, Jatoi A. Cumulative morbidity and late mortality in long-term survivors of exocrine pancreas cancer. J Gastroinstestinal Cancer 2009, 40:46-50.
5. Spinelli GP, Zullo A, Romiti A, Di Seri M, Tomao F, Miele E, Spalletta B, Eramo A, Hassan C, Tomao S. Long-Term Survival in Metastatic Pancreatic Cancer. A Case Report and Review of the Literature. JOP J Pancreas (Online) 2006, 7:486-491.
6. Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, Strasberg S, Hanna S, Taylor B, Langer B, Gallinger S. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 2004, 198:722-731. 10.1016/j.jamcollsurg.2004.01.008, 15110805.
7. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas HO, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981, 48:1705-1710. 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4, 7284971.
8. Abbott DE, Baker MS, Talamonti MS. Neoadjuvant Therapy for Pancreatic Cancer: A Current Review. J Surg Oncol 2010, 101:315-320. 10.1002/jso.21469, 20187063.
9. Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK, Pitt HA, Lillemoe KD, Cameron JL. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997, 225:621-636. 10.1097/00000658-199705000-00018, 1190807, 9193189.
10. Saini A, Norman AR, Cunningham D, Chau I, Hill M, Tait D, Hickish T, Iveson T, Lofts F, Jodrell D, Ross PJ, Oates J. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 2003, 88:1859-1865. 10.1038/sj.bjc.6600995, 2741111, 12799627.
11. Duffour J, Bouché O, Rougier P, Milan C, Bedenne L, Seitz JF, Buecher B, Legoux JL, Ducreux M, Vetter D, Raoul JL, François E, Ychou M. Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial). Anticancer Res 2006, 26:3877-3883.
12. Pasetto LM, Jirillo A, Stefani M, Monfardini S. Old and new drugs in systemic therapy of pancreatic cancer. Crit Rev Oncol Hematol 2004, 49:135-151. 10.1016/S1040-8428(03)00170-7, 15012974.
13. Trudeau ME. Docetaxel: a review of its pharmacology and clinical activity. Can J Oncol 1996, 6:443-457.
14. Rougier P, Adenis A, Ducreux M, de Forni M, Bonneterre J, Dembak M, Clouet P, Lebecq A, Baille P, Lefresne-Soulas F, Blanc C, Armand JP. A phase II study: Docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000, 36:1016-1025. 10.1016/S0959-8049(00)00072-1, 10885606.
15. Mason K, Hunter N, Abbruzzese J. In vivo enhancement of tumor radio response by Taxotere (TXT). Proc Annu Meet Am Soc Clin Oncol 1997, 16:775a.
16. Choy H, Rodriguez F, Wilcox B. Radiation-sensitizing effects of taxotere. Proc Annu Meet Am Assoc Cancer Res 1992, 33:2991a.
17. Di Cosimo S, Ferretti G, Fazio N, Silvestris N, Carlini P, Alimonti A, Gelibter A, Felici A, Papaldo P, Cognetti F. Docetaxel in advanced gastric cancer: Review of the main clinical trials. Acta oncologica 2003, 42:693-700. 10.1080/02841860310011014, 14690154.
18. Fleming TR. One sample multiple testing procedure for phase II trials. Biometrics 1982, 38:143-205. 10.2307/2530297, 7082756.
19. Morganti AG, Massaccesi M, La Torre G, Caravatta L, Piscopo A, Tambaro R, Sofo L, Sallustio G, Ingrosso M, Macchia G, Deodato F, Picardi V, Ippolito E, Cellini N, Valentini V. A Systematic Review of Resectability and Survival After Concurrent Chemoradiation in Primarily Unresectable Pancreatic Cancer. Ann Surg Oncol 2010, 17:194-2005. 10.1245/s10434-009-0762-4, 19856029.
20. Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, Small W, Safran H, Wanebo HJ. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol 2004, 27:51-56. 10.1097/01.coc.0000046300.88847.BF, 14758134.
21. Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA. Cancer and leukemia group B (CALGB) 89805: Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 2003, 34:107 116.
22. Haddock MG, Swaminathan R, Foster NR, Hauge MD, Martenson JA, Camoriano JK, Stella PJ, Tenglin RC, Schaefer PL, Moore DF, Alberts SR. Gemcitabine, Cisplatin, and Radiotherapy for Patients With Locally Advanced Pancreatic Adenocarcinoma: Results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol 2007, 25:2567-2572. 10.1200/JCO.2006.10.2111, 17577035.
23. Reyes-Gibby CC, Abbruzzese JL, Xiong HQ, Ho L, Evans DB, Varadhachary G, Bhat S, Wolf RA, Crane C. Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation. J Pain Symptom Manage 2007, 34:244-252. 10.1016/j.jpainsymman.2006.11.007, 2084477, 17513082.
24. Schwartz AL, Nail LM, Chen S, Meek P, Barsevick AM, King ME, Jones LS. Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. Cancer Invest 2000, 18:11-19. 10.3109/07357900009023057, 10701362.
25. Nagahama T, Ando M, Ohara T, Ganno H, Hataji K, Ami K, Fukuda A, Maruyama M. A case report of un-resectable pancreas body carcinoma successfully treated by chemoradiotherapy. Gan to Kagaku Ryoho 2009, 36:2425-2427.
26. Hoshino H, Takeda Y, Nagano H, Nakamori S, Kobayashi S, Eguchi H, Marubashi S, Tanemura M, Kitagawa T, Umeshita K, Monden M, Doki Y, Mori M. A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by s-1 and gemcitabine combination chemotherapy. Gan To Kagaku Ryoho 2009, 36:2419-2421.
27. Ohmura Y, Takeda Y, Nagano H, Nakamori S, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Kitagawa T, Monden M, Mori M, Doki Y. A case of locally advanced pancreatic cancer with superior membrane artery invasion successfully resected after gemcitabine-based chemoradiotherapy. Gan To Kagaku Ryoho 2009, 36:2428-2429.
28. Peros G, Sakorafas GH, Giannopoulos GA, Manikis D, Vassiliu P, Brountzos EN. Successful Pancreaticoduodenectomy with Immediate Vascular Reconstruction in a Patient with Cancer of the Pancreatic Head and Celiac Artery Stenosis. A Case Report. JOP J Pancreas (Online) 2009, 10:667-670.
29. Ahmad NA, Lewis JD, Ginsberg GG, Haller DG, Morris JB, Williams NN, Rosato EF, Kochman ML. Long term survival after pancreatic resection for pancreatic adenocarcinoma. The American Journal of Gastroenterology 2001, 96:2609-2615. 10.1111/j.1572-0241.2001.04123.x, 11569683.
30. Connoly MM, Dawson PJ, Mhicelassi F, Moossa AR, Lowenstein F. Survival in 1001 Patients with Carcinoma of the Pancreas. Ann of Surg 1987, 206:366-370.
31. Chen EL, Prinz RA. Long-term survival after pancreatic cancer treatment. Am J Surg 2007, 194:s127-s130.